title: A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.
abstract: This report describes the design, methods and clinical results of a prospective sequential multinational (5 countries) study conducted to evaluate the effects of subcutaneous sumatriptan on health-related quality of life, workplace productivity, clinical parameters and patient satisfaction. Adult patients with moderate to severe migraine initially received customary therapy for migraine episodes for 12 weeks, followed by 24 weeks' treatment with self-administered subcutaneous sumatriptan 6 mg. Demographic, baseline, health-related quality of life and patient satisfaction rating data were collected during visits to the clinic. Data relating to migraine symptoms, migraine therapy, work productivity and non-work activity time were collected on diary cards filled out by the patients. 749 patients were recruited to the study and 637 received at least 1 dose of sumatriptan. Overall, 75.5% of migraines were successfully treated within 2 hours with sumatriptan compared with 31.9% with customary therapy; 36% of patients reported complete relief at 2 hours with sumatriptan treatment compared with 1% of patients receiving customary therapy. 69% of patients successfully treated 70% of their migraines with sumatriptan within 2 hours, compared with 12% of patients with customary therapy. No serious adverse events were reported; 50% of patients reported an adverse event during the 12-week customary therapy phase and 89% of patients during the 24-week sumatriptan phase. These clinical results, which are consistent with those reported in randomised blinded studies of subcutaneous sumatriptan, suggest that relief of migraine symptoms occurs more often, and in less time, in patients receiving subcutaneous sumatriptan rather than customary therapy as their primary medication.
authors.affiliation: Royal Melbourne Hospital, Parkville, Victoria, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Heywood
authors.forename: J
authors.initials: J
authors.lastname: Bouchard
authors.forename: P
authors.initials: P
authors.lastname: Cortelli
authors.forename: C
authors.initials: C
authors.lastname: Dahlöf
authors.forename: J P
authors.initials: JP
authors.lastname: Jansen
authors.forename: S
authors.initials: S
authors.lastname: Pham
authors.forename: J
authors.initials: J
authors.lastname: Hirsch
authors.forename: C E
authors.initials: CE
authors.lastname: Edwards
authors.forename: J
authors.initials: J
authors.lastname: Adams
authors.forename: P
authors.initials: P
authors.lastname: Berto
authors.forename: B
authors.initials: B
authors.lastname: Brueggenjuergen
authors.forename: A L
authors.initials: AL
authors.lastname: Nyth
authors.forename: P
authors.initials: P
authors.lastname: Lindsay
authors.forename: K L
authors.initials: KL
authors.lastname: Price
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects